Physician profile

Vijay A Mehta

Cardiovascular Disease · Elkhart, IN

NPI 1801921325

$5,105.99

in general payments reported to CMS, 2019-2025

44 companies · $234 in 2025

The $234 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

See the full distribution for Cardiovascular Disease

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,501.33

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $1,264.76 2019-2024
Abbott Laboratories $510.91 2021-2025 Freestyle Libre 3, Cardiomems, Mitraclip
Janssen Pharmaceuticals, INC $474.43 2019-2022
Bayer Healthcare Pharmaceuticals INC. $306.39 2021-2025
Merck Sharp & Dohme LLC $266.18 2022-2025 Verquvo, Capvaxive
Boston Scientific Corporation $255.19 2022-2024 Watchman Flx
Amgen INC. $254.38 2019-2022
Pfizer INC. $248.36 2019-2025
Edwards Lifesciences Corporation $158.25 2020-2021
Cvrx, INC. $152.72 2024 Barostim Neo System
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $117.62 2020-2021
Beta Bionics, INC. $113.72 2024 Ilet Bionic Pancreas
Sanofi-Aventis U.S. LLC $88.25 2019-2021
Actelion Pharmaceuticals US, INC. $69.14 2022
Kiniksa Pharmaceuticals, LTD. $65.75 2021
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Impulse Dynamics (USA) INC. $59.61 2022
E.R. Squibb & Sons, L.L.C. $58.04 2020-2021
Boehringer Ingelheim Pharmaceuticals, INC. $54.41 2020-2023 Jardiance
Esperion Therapeutics, INC. $52.21 2021-2022
Kowa Pharmaceuticals America, INC. $51.32 2020-2021
Chiesi USA, INC. $49.31 2020-2021
Amarin Pharma, INC. $47.28 2021-2022
Atricure, INC. $44.69 2023
Astellas Pharma US INC $42.04 2020-2021
Akcea Therapeutics, INC. $41.85 2020-2021
Regeneron Healthcare Solutions, INC. $29.44 2021-2022
Recordati_rare_diseases_inc. $24.07 2023 Isturisa, Signifor Lar
Scpharmaceuticals INC. $21.72 2024
Lexicon Pharmaceuticals, INC. $21.49 2023 Inpefa
Irhythm Technologies, INC. $20.84 2023 Zio Xt Patch
Kiniksa Pharmaceuticals International, Plc $19.57 2024 Arcalyst
Cardiva Medical, INC. $19.19 2021
Teva Pharmaceuticals USA, INC. $18.30 2022
Amneal Pharmaceuticals LLC $16.81 2024 Unithroid
Zyla Life Sciences, INC. $16.33 2019
Astrazeneca Pharmaceuticals LP $15.11 2019
Medtronic Vascular, INC. $14.23 2020
Lundbeck LLC $11.25 2020
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $10.83 2019

5 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Vijay A Mehta

$5,105.99

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $234 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/81501/vijay-a-mehta

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.